Neural correlates of reward processing in schizophrenia — Relationship to apathy and depression

https://doi.org/10.1016/j.schres.2009.11.007Get rights and content

Abstract

The present study employs a new framework to categorise the heterogeneous findings on the relationship between impaired reward processing and negative and affective symptoms of schizophrenia. Based on previous behavioural and neuroimaging studies we postulate that “wanting” (i.e. anticipation) of a reward is specifically related to apathy, whereas “liking” (i.e. hedonic impact) is related to anhedonia and depression — symptoms commonly observed in schizophrenia. Fifteen patients with schizophrenia or schizoaffective disorder treated with atypical antipsychotic drugs and fifteen healthy controls performed a probabilistic monetary incentive delay task while undergoing functional magnetic resonance imaging. At the group level we found no significant differences between patients and controls in neural activation during anticipation or receipt of a reward. However, in patients with schizophrenia specific relationships between ventral–striatal activation and symptoms were observed. Ventral–striatal activation during reward anticipation was negatively correlated with apathy, while activation during receipt of reward was negatively correlated with severity of depressive symptoms. These results suggest that the link between negative symptoms and reward anticipation might specifically relate to apathy, i.e. a lack of motivation and drive. Impaired hedonic reward processing might contribute to the development of depressive symptoms in patients with schizophrenia, but it is not directly associated with self-rated anhedonia. These results indicate the necessity of more specifically differentiating negative and affective symptoms in schizophrenia in order to understand the role of the reward system in their pathogenesis.

Introduction

The mesolimbic dopamine system is crucial for the processing of reward-related information and appears to be dysfunctional in patients with schizophrenia (Abi-Dargham et al., 2000). The importance of this system in the pathophysiology of schizophrenia has been highlighted in recent studies investigating the relationship between the neural processing of rewards and schizophrenic symptoms (Juckel et al., 2006b, Waltz et al., 2008).

More specifically, the “wanting” of a reward, which arises from its motivational incentive value (Berridge and Robinson, 1998), appears to be directly impaired in schizophrenia. Both unmedicated patients with schizophrenia and those treated with typical antipsychotics show reduced activation of the ventral striatum (VS) during reward anticipation (Juckel et al., 2006a, Kirsch et al., 2007, Schlagenhauf et al., 2008). Furthermore, a negative correlation has been found between VS activation and overall negative symptoms in unmedicated patients with schizophrenia (Juckel et al., 2006b).

Group differences in brain activation during the receipt of a reward (i.e., “liking”) have received less attention than differences arising during reward anticipation. One study compared patients treated with typical and atypical antipsychotics and found no differences during the processing of a rewarding outcome (Kirsch et al., 2007). In contrast, a further study demonstrated that higher delusional symptoms were associated with smaller medial-prefrontal-activation differences between successful and unsuccessful loss-avoidance in unmedicated patients with schizophrenia (Schlagenhauf et al., 2009).

The nature of the impairment in different stages of neural reward processing and the relationship between these stages and the negative symptoms observed in schizophrenia (e.g.: anhedonia, apathy) are thus subject to continued debate. Here, we propose a simple framework which integrates the heterogeneous findings on reward-processing impairments in schizophrenia by relating specific aspects of negative symptoms to different stages of reward processing and the corresponding structures of the dopaminergic reward system (Fig. 1).

Reward anticipation or the “wanting” of a reward has been associated with motivational processes which promote goal-directed behaviours that aim to achieve desired rewards (Schultz, 2002). Apathy or a loss of motivation, which leads to the reduction of goal-directed behaviours (Marin, 1991), may be specifically related to deficits at this stage of reward processing. Apathy is considered to be a common but treatment-resistant symptom (Buckley and Stahl, 2007) and has been conceptualised as a lack of responsiveness to stimuli and self-initiated action (Stuss et al., 2000). This symptom might therefore be a direct consequence of the diminished activation of the VS observed in patients with schizophrenia during anticipation (Fig. 1a).

The hedonic impact or the “liking” of a reward has been linked to activity in prefrontal areas and specifically to the medial orbitofrontal cortex (mOFC) (Kringelbach, 2005), whereas the VS codes positive prediction errors in response to unexpected rewards (Berns et al., 2001). Impaired neural processing during this stage of reward processing may be independent from motivational components given that hedonic impact has been found to be independent from anticipation effects (Gard et al., 2007, Kring and Neale, 1996). Anhedonia and depression represent common yet distinct symptoms of schizophrenia and are both negatively related to experiences of positive emotions in daily life (Horan et al., 2006, Pizzagalli et al., 2005, Siris, 2000). Both symptoms are additionally characterised by an altered reward circuitry (Holcomb and Rowland, 2007, Martin-Soelch, 2009). Consequently, blunted responses to rewarding outcomes may be related to these symptoms (Fig. 1b).

In the present study, we compared the neural activation of healthy controls and patients with schizophrenia treated with atypical neuroleptics during both reward anticipation and outcome. Our main goal was to relate specific symptoms of schizophrenia – notably apathy, anhedonia, and depression – to changes in neural activity during the different stages of reward processing.

Section snippets

Participants

We included 15 right-handed healthy controls and 15 right-handed patients with schizophrenia or schizoaffective disorder. Patients with schizophrenia were recruited at the Psychiatric Hospital of the University of Heidelberg. A structured clinical interview for DSM-IV, the MINI (Sheehan et al., 1998), was employed to confirm diagnoses and to rule out both other DSM Axis I disorders and current drug abuse. All patients were medicated with atypical antipsychotics (four clozapine, three

Demographic, clinical and behavioural data

Demographic, clinical and behavioural data are summarised in Table 1. There were no significant group differences with respect to age, education, reaction times, or the total amount of money earned. Patients with schizophrenia rated the reward cues and targets as more arousing than healthy controls (reward cues t = 2.5, p = 0.018, targets t = 2.1, p = 0.041) and displayed greater physical-anhedonia scores (t = 2.36, p = 0.013).

fMRI data

In order to identify significant activations in the contrasts of interest for

Discussion

We found that patients with schizophrenia treated with atypical antipsychotic drugs performed as well as healthy controls during the monetary incentive delay task. At the group level there were no significant differences between patients and controls in neural activation during anticipation or receipt of a reward. These observations correspond with most (Juckel et al., 2006a, Kirsch et al., 2007, Schlagenhauf et al., 2008) but not all previous studies (Waltz et al., 2008). More importantly and

Role of funding source

Joe J. Simon is supported by a doctoral scholarship from the state of Baden-Wuerttemberg through the Landesgraduiertenförderung (LGFG). The LGFG had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Contributors

Joe Simon and Stefan Kaiser designed the study and wrote the protocol. Matthias Weisbrod and Daniela Roesch-Ely reviewed the protocol and contributed to the analytic approach. Joe Simon, Stephan Walther and Armin Biller collected the data. Joe Simon, Stephan Walther, Christoph Stippich and Armin Biller undertook the statistical analyses and prepared them for presentation. Joe Simon and Stefan Kaiser wrote the first draft of the manuscript. All authors contributed to and have approved the final

Conflict of interest

All authors declare that they have no conflicts of interest.

References (52)

  • F. Schlagenhauf et al.

    Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions

    Biol. Psychiatry

    (2009)
  • W. Schultz

    Getting formal with dopamine and reward

    Neuron

    (2002)
  • J.J. Simon et al.

    Neural reward processing is modulated by approach- and avoidance-related personality traits

    Neuroimage

    (2010)
  • A. Ströhle et al.

    Reward anticipation and outcomes in adult males with attention-deficit/hyperactivity disorder

    Neuroimage

    (2008)
  • A. Abi-Dargham et al.

    Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

    Proc. Natl. Acad. Sci. U. S. A.

    (2000)
  • B. Abler et al.

    Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study

    Psychopharmacology

    (2007)
  • B. Abler et al.

    Neural correlates of frustration

    Neuroreport

    (2005)
  • G.S. Berns et al.

    Predictability modulates human brain response to reward

    J. Neurosci.

    (2001)
  • K.P. Bhatia et al.

    The behavioural and motor consequences of focal lesions of the basal ganglia in man

    Brain

    (1994)
  • R.A. Bressan et al.

    The role of dopamine in reward and pleasure behaviour; review of data from preclinical research

    Acta Psychiatr. Scand.

    (2005)
  • M. Brett et al.

    Region of interest analysis using an SPM toolbox

    Neuroimage

    (2002)
  • P.F. Buckley et al.

    Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or Cul-de-sac?

    Acta Psychiatr. Scand.

    (2007)
  • G. Burgdörfer et al.

    Physische und soziale anhedonie. Die Evaluation eines Forschungsinstruments zur Messung einer psychopathologischen Basisstörung

    Eur. Arch. Psychiatry Clin. Neurosci.

    (1987)
  • A.M. Dale

    Optimal experimental design for event-related fMRI

    Hum. Brain Mapp.

    (1999)
  • G. Foussias et al.

    Negative symptoms in schizophrenia: avolition and Occam's razor

    Schizophr. Bull.

    (2008)
  • K.J. Friston et al.

    Statistical parametric maps in functional imaging: a general linear approach

    Hum. Brain Mapp.

    (1995)
  • Cited by (0)

    View full text